Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system with a strong genetic component. Variation in the major histocompatibility complex on chromosome 6p21, specifically the HLA-DRB1*15 haplotype, is the strongest genetic factor for MS, yet it is estimated to account for only a portion of risk for the disease. Previous evidence has implicated the nitric oxide synthase gene (NOS2A) encoding inducible NOS on chromosome 17q11 as a potential MS susceptibility gene. To determine whether variation in the NOS2A gene contributes to MS risk, we investigated a total of 50 polymorphisms within or flanking the locus for evidence of association using a comprehensive analytical strategy. A total of 6265 members from 1858 well-characterized MS families were utilized. No evidence for overtransmission of any individual single-nucleotide polymorphism allele or haplotype to the MS-affected individuals was observed. Furthermore, different transmission rates were not observed in either DRB1*15-positive or DRB1*15-negative family subgroups, or when extreme clinical outcomes characterizing disease progression were examined. The very largest study of NOS2A variation in MS, to date, excludes even a modest role for this locus in susceptibility.
Introduction
Nitric oxide synthase 2A (NOS2A) catalyzes the synthesis of the free radical nitric oxide (NO), an important mediator of several physiologic processes, including regulation of vascular tone, host defense against parasites, immune modulation and neurotransmission. However, excessive amounts of NO in the brain have been linked to tissue injury and ensuing neurological symptoms as a result of mitochondrial dysfunction and direct killing of oligodendrocytes and axons. [1] [2] [3] For example, in the multiple sclerosis (MS) brain the transcriptional regulation of the NOS2A gene in activated microglia, astrocytes and macrophages is well documented. [4] [5] [6] [7] Furthermore, chronic inactive noninflammatory MS lesions, and even normal appearing white matter, have elevated concentrations of NO, 8 suggesting an effector role for this molecule in disease development. Aminoguanidine, a selective inhibitor of NO, prevented the clinical development of experimental autoimmune encephalomyelitis in rodents with reduction of both inflammation and demyelination. 9, 10 MS is a common neurologic disease with an important genetic component. 11 Given its functional profile, NOS2A has been considered by several authors to be a plausible disease susceptibility candidate gene. Moreover, its putative involvement in complex genetic disorders may go beyond autoimmune demyelination. Linkage in a subset of type I diabetes pedigrees (HLA-DR3/4 positives) 12 and genetic associations with diabetic renopathy, 13 dementia with Lewy bodies, 14 coronary artery disease, 15 malaria 16, 17 and Parkinson's disease 18, 19 have been reported. We previously reported a NOS2A exon 10 single-nucleotide polymorphism (SNP, C/T, D346D) being associated with disease susceptibility in two independent MS datasets. 20 Evidence for excess transmission of the T allele remained significant even after correction for multiple testing in HLA-DRB1*15-positive families. Because the associated SNP confers a synonymous coding change, and other smaller NOS2A studies in MS have either suggested trends 21, 22 or failed to detect an association, [23] [24] [25] much larger studies are needed to confidently confirm or exclude a role for this important locus in disease susceptibility.
NOS2A maps to 17q11 and comprises 27 exons with translation initiation and termination codons in exon 2 and exon 27, respectively. 26 The largest familial MS dataset, to date, was assembled for this study, including more than 2100 MS cases and over 6200 family members, to comprehensively investigate the NOS2A locus in MS. No significant association was detected.
Results
A comprehensive analytical approach ( Figure 1) 20 was not replicated when the UK families were considered separately (928 trios; 301 T:316 NT, P ¼ 0.54, data not shown). All SNPs (rs no.) with exact map locations, minor allele frequencies and results from testing HardyWeinberg equilibrium (HWE) are included in Supplementary Table S1 .
Discussion
MS clusters with the so-called complex genetic diseases, a large group of common disorders characterized by modest disease risk heritability and multifaceted interactions with environmental influences. Previous efforts to screen the genome for linkage using low-density maps of microsatellite markers have only been modestly successful. [28] [29] [30] More recently, a high-density SNP panel was used to perform a linkage study of 730 multiple affected MS families. 31 Although the results revealed linkage with genome-wide significance in the major histocompatibility complex (MHC) region on chromosome 6p21, no other regions with significant evidence for linkage were Figure 1 Description of analyses. The total number of unique multiple sclerosis (MS) families across the three datasets was 1858: comprised of 1582 total trios, 2159 unique MS cases and 4106 family members. Although MS families were not completely independent across all the three analyses, the study design maximized use of all available genetic data for analyses of allelic, genotypic and haplotypic associations across the nitric oxide synthase 2A (NOS2A) locus (see Materials and methods for full description).
identified. Variation in the MHC, specifically the HLA-DRB1*15 haplotype, is the strongest known genetic factor for MS, and results from multiple studies support this association. 32, 33 The complex contribution from this region, however, is estimated to account for only a portion of the risk for the disease. On the basis of these results, it is clear that common (frequency 45 to 10%) non-MHC MS susceptibility alleles confer quite modest risk (odd ratios o2), and are difficult to detect using linkage studies. Association studies, in comparison, have much greater statistical power to detect modest disease risk variants. 34 On the basis of the proposed effect size for genetic factors in MS, power calculations show that association studies require large sample sizes (for example 500-1500 families or cases and equal numbers of controls). 35 A large number of published association studies for MS, to date, are substantially underpowered; very few MS candidate genes, including NOS2A, have been properly interrogated, and even fewer have been truly excluded. Results from the first genome-wide SNP association study in MS also underscore the need to carefully evaluate potential candidate genes with modest effects. Genetic variation in nitric oxide synthase 2A
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Our investigation has a number of strengths. Highdensity coverage of the extended NOS2A region on chromosome 17q11 was comprehensive and comprised of high-quality, informative SNP genotypes. The total number of SNPs, either genotyped in the current study or highly correlated with genotyped SNPs (r 2 X0.80), based on available CEU data (www.hapmap.org) was 32 (within NOS2A locus boundaries), and numbered, in total, 151 across the extended NOS2A region (data not shown; see 'Materials and methods'). This resulted in an average marker density for the NOS2A gene one SNP per 1.6 kb, and an average marker density for the NOS2A-extended region of one SNP per 2.2 kb. In addition, our large family-based design was well powered and robust to spurious results due to population stratification. We also included analyses of extended NOS2A haplotypes and genotypes, in addition to allelic tests of association to ensure no genetic effects were missed. Haplotype analyses were based on assigned blocks using conventional methods, 27 and further extended our coverage of untyped NOS2A genetic variants in this genomic region. Finally, given the importance of DRB1*15 in MS, we stratified families based on carrier status of this risk allele for analyses of all NOS2A SNPs and haplotypes to look for differences. Previous results suggested NOS2A associations were more prominent in DRB1*15-positive MS cases 20, 21 and/or families, however the current study does not confirm this finding.
We cannot exclude the potential role of other, yet unidentified, genetic or environmental factors interacting with NOS2A to influence the risk for MS modulate disease course. NOS2A interactions with exposure to tobacco smoke have been reported for Parkinson's disease. 18 Whether this gene-environment relationship is important in MS, given the strong evidence for smoking as a MS risk factor 37, 38 will need to be investigated. The characterization and inclusion of such cofactors in analyses of all candidate genes in MS may help explain discrepancies between individual studies. The next generation of risk factor studies in MS must incorporate both genetic and environmental exposure data and the application of sophisticated analytical strategies to identify modest interactions influencing risk, particularly in the absence of main effects. This is virtually unexplored territory in MS research. Further, although common coding region NOS2A variants were genotyped and/or captured and subsequently excluded as major risk factors for MS in the present study, a few very rare nonsynonymous NOS2A variants have been reported (dbSNP; minor allele frequency, MAF oo0.05 or unknown) but were not interrogated in the current study. Risk for disease due to rare variants, perhaps in particular subsets of MS, therefore, cannot be excluded.
A role for genetic factors influencing clinical outcome in MS is also strongly supported by several lines of evidence. Twin studies demonstrate that concordance of disease course is higher in monozygotic twins when compared to dizygotic twins or siblings; 39 family studies in MS have reported similar results. 40 Although several clinical MS phenotypes have been pursued for genetic studies, one strategy is to compare individuals who are discordant for long-term outcomes. Here, we examined MS cases lying at opposite extremes of the distribution of long-term disability ('mild' and 'severe' disease subgroups) as defined previously. 41, 42 A resulting loss of statistical power can be expected with a smaller sample size; however, the anticipated increase in clinical homogeneity of these two subgroups is also expected to increase power to detect genetic influences.
Our results demonstrate that common variation within NOS2A, alone, does not appear to significantly influence disease severity defined by long-term disability. However, in order to identify genetic or other risk factors that influence disease severity in MS, it needs to be determined whether radiologic relapses on magnetic for details). Blocks were assigned using Haploview (v.4.0) and standard parameters as previously described. 27 The yellow highlighted area in each plot corresponds to the location on chromosome 17q11 for NOS2A locus boundaries, including both 5 0 and 3 0 -untranslated regions (chromosome 17:23107920-23159761). Plotted P-values in Figure 3b correspond to the exact map location of the first NOS2A SNP in each haplotype block. Haplotype analyses were performed in multiple sclerosis (MS) trio families only (see Supplementary Table S4 for details). The total number of SNPs within the boundaries of the NOS2A gene that were either genotyped or tagged by SNPs in our study ¼ 32 (Build 36) based on HapMap CEU data (www.hapmap.org and r 2 X0.80; Tagger in Haploview, v.4.0.). A total of 151 SNPs were genotyped or tagged across the extended NOS2A region based on the same criteria (data not shown). This resulted in an average marker density for the NOS2A gene of one SNP per 1.6 kb, and an average marker density for the NOS2A-extended region of one SNP per 2.2 kb. Confounding remains possible in studies that do not include this information, particularly if MS cases with distinct genotypes respond differentially to particular treatments. In order to fully dissect the role of candidate genes like NOS2A and others as disease course modifiers in MS, large longitudinal studies that also include human leukocyte antigen (HLA) class II data, gender and use of therapeutics, and that capture comprehensive phenotypic information as well as serial MRI measurements, will be required.
In summary, results presented here from the largest study of NOS2A variation in MS performed, to date, provide strong evidence for exclusion of common variants in NOS2A underlying susceptibility or affecting disease progression defined by very modest or extreme disability. Molecular methods and our knowledge of the complex genetic landscape in MS have improved considerably over the past 3 years. Our findings contribute to the understanding of NOS2A variation and MS, and underscore the importance of using large sample sizes to detect modest genetic effects.
Materials and methods
To determine whether NOS2A variation might play a role in susceptibility to MS, we analyzed a total of 50 unique polymorphisms across the NOS2A locus and flanking genomic regions. A comprehensive analytical approach ( Figure 1 ) was utilized that included a total of 1858 unique families (2159 MS cases, 4106 unaffected family members) of European descent recruited from the United States and the United Kingdom and maximized use of all available genetic data ( Table 1) . A total of 427 US families from the original study were included. 20 The diagnostic criteria, ascertainment protocols and clinical and demographic characteristics of these populations are described in more detail elsewhere. 31, 32, 36, 45 The EDSS 46 was used in conjunction with disease duration to define very mild or severe forms of MS as a secondary phenotype for analysis, as previously described. 32 Disease duration was measured as the number of years between the year of onset of first symptom and year of last exam with EDSS assessment; in most cases this is at the entry of the study, given the cross-sectional nature of these datasets. Mild disease (the ability to walk normally or have only mild gait disability) was defined as those cases with an EDSS p3 after 15 years. Severe disease (need for bilateral assistance to walk or wheelchair dependency), included cases who reached an EDSS 46, within 10 years of disease duration. Appropriate institutional review boards approved this study and all participants gave written informed consent.
Genotyping and quality control Analysis 1. The promoter region (8.3 kb), 27 exons and all exon-intron junctions of the NOS2A gene (43.7 kb) were resequenced in 20 Caucasian MS cases to confirm reported SNPs and identify new SNPs. Primer sequences were designed using Oligo 6.8 software (Molecular Biology Insights Inc., Cascade, CO, USA) and ordered from Operon Biotechnologies Inc. (Huntsville, AL, USA) . PCR was carried out in a total volume of 50 ml containing 20 ng DNA, 1 Â AmpliTaq Gold Buffer (Applied Biosystems, Foster City, CA, USA), 0.5 mM NOS2A region-specific forward and reverse primers, 0.8 mM deoxyribonucleotide triphosphate mix, 2.5 units AmpliTaqGold DNA polymerase (Applied Biosystems) and 1.5-3.5 mM MgCl 2 . Amplification was carried out in a PTC-100 Thermal Controller (MJ Research Inc., Waltham, MA, USA) with an initial temperature of 95 1C for 10 Table S1 ). The products were then purified using QIAquick PCR purification kit under manufacturer's conditions (Qiagen Inc., Valencia, CA, USA). The purified samples were sent to the UC San Francisco Core Facility for sequencing. Direct sequencing was employed to identify sequence variation. Sequence data were analyzed using Sequencher 4.8 software (Gene Codes Corporation, Ann Arbor, MI, USA). A total of 52 SNPs were identified within the NOS2A locus. Using an MAF cutoff ¼ 0.1, a total of 41 from 52 SNPs were chosen for genotyping (Supplementary Table S2 ) in 203 unrelated individuals from the US MS families. All SNPs were genotyped using ABI custom TaqMan assays on File Builder 2.0 software. Analysis of haplotype block structure defined by the 41 SNPs identified a total of 15 loci as tagging SNPs for 6 haplotype blocks within the NOS2A locus (Figure 2) . A total of 1648 MS families (N ¼ 5635 total individuals, 1949 MS cases) including 1372 full trio families were genotyped for the 15 tagging NOS2A SNPs using the same genotyping assays. Sequenced base control DNA samples were included for each 384 well plate to ensure genotyping accuracy and reproducibility (499%). All MS families were examined for Mendelian inconsistencies using PedCheck 47 and any discrepancies were addressed through regenotyping or omission from the analyses when problems could not be resolved. A full description of NOS2A region SNPs, including location, MAF and all results from HWE tests are included in Supplementary Table S3 .
Analysis 2. Genetic data derived for 930 MS trios (N ¼ 3060 individuals, 930 MS cases) for 40 NOS2A locus or nearby SNPs were included in this study. Genotyping was performed using a DNA microarray (GeneChip Human Mapping 500K Array Set, Affymetrix, Santa Clara, CA, USA). Sample preparation, and quality control measures for both genotyping and DNA samples, including exclusion criteria based on Mendelian error rate have been previously described. 36 Only SNP markers with MAF X0.05 were included in this study. A full description of NOS2A region SNPs, including location, MAF and all results from HWE tests are included in Supplementary Table S3 .
Analysis 3. Genotype data (a total of 50 unique NOS2A region SNPs) derived from analysis 1 and analysis 2 were combined for a comprehensive assessment of NOS2A variation. A total of 720 MS families (N ¼ 2160 individuals, 720 MS cases) were available for analysis. The total NOS2A region coverage was 335 kb; marker density ¼ one SNP per 6.9 kb. The marker density for the NOS2A gene, specifically (spanning 46 kb), was one SNP per 2.0 kb. Cross-platform validation was performed for three NOS2A SNPs (rs3729508, rs944724 and rs2734299) that were genotyped and evaluated for a total of 2160 individuals using both Affymetrix and Taqman platforms. A low error rate (o0.5%) was observed when individual genotypes were compared, demonstrating that genotypes derived from both platforms were concordant (data not shown).
HLA-DRB1 genotyping. DRB1*15 carrier status was available for 1114 of total 2159 MS cases (51.9%) included in this study. Medium-resolution typing of HLA-DRB1 (two to four digits) was performed as previously described. 32, 45 A total of 6 of 1045 MS cases without HLA-DRB1 genotype data were genotyped for the rs3135388 (A/G) SNP to identify the MS-associated DRB1*15 allele, as the presence of this allele and the rs3135388A SNP are highly correlated. 48, 49 Our own previous work based on data from 2750 individuals demonstrates 499% concordance between DRB1*15 and rs3135388A. 36 Therefore, a total of 1120 families were stratified for NOS2A single SNP and haplotype analyses in order to detect differences that might be present between these two subgroups defined by DRB1*15 status.
Statistical analysis
All NOS2A SNP genotypes were tested for deviation from Hardy-Weinberg expectations in unrelated family founders and MS cases using Haploview (v.4.0). 50 Markers were excluded if Po0.01 in either group. One marker was dropped from final analyses. Pairwise linkage disequilibrium (LD) measures (D 0 and r
2
) and significance were calculated using Haploview (v.4.0) 50 and standard parameters were used for characterization of haplotype blocks and initial identification of tagged SNPs (analysis 1). 27 Family-based analyses of single NOS2A SNPs were performed using the pedigree disequilibrium test or PDT (v.5.1). 51, 52 The PDT is a powerful analytical method that uses genetic data from related nuclear families and discordant sibships within extended pedigrees. Two PDT statistics were used: the PDT-sum statistic, which examines allelic effects, and the genotype-PDT that examines genotypic effects. All trio MS families were analyzed for single SNP associations using the transmission disequilibrium test (TDT) 53 implemented in Haploview (v.4.0). 50 Family-based analyses of variation in haplotype blocks in MS trios was performed using algorithms implemented in Haploview (v.4.0) to identify block structure for haplotype assessment, and the Unphased (v.3.0.10) 54 software to perform global tests for haplotype association. For Unphased, the TDT-uncertain option was used, which implements unconditional logistic regression on the full likelihood of parents and offspring as previously described. 55 The expectation-maximization algorithm implemented in Unphased was used to obtain maximium-likelihood estimates of case (transmitted) and control (nontransmitted) parental haplotype frequencies under both null and alternative hypotheses. For 'N' haplotypes, the global test is an NÀ1 degree-of-freedom test, jointly testing all haplotypes. Mild (total N ¼ 101) and severe (total N ¼ 104) MS cases were also compared for differences in NOS2A SNP allele and haplotype frequencies using Haploview (v.4.0). 50 A type 1 error rate (a) of 0.001 was utilized for interpretation of results, and was based on: (1) the number of statistical tests performed in this study, and (2) the fact that this was an investigation of a previously implicated candidate gene (strong apriori evidence for association). The Tagger algorithm in Haploview (v.4.0) was used with our genotype data to evaluate tagged (but untyped) NOS2A SNPs based on HapMap CEU data (www.hapmap.org) and r 2 X0.80 as previously described. 56 
Statistical power
On the basis of our family sample sizes ranging from 720 to 1648 trios, we calculated power for TDT analyses under a multiplicative model using the TDT Power Calculator (http://www.biostat.jhsph.edu/~wmchen/ pc.html) as previously described. 56 We assumed a very conservative type 1 error rate of 0.1% (a ¼ 0.001, based on multiple tests in the current investigation), and complete LD between marker and disease allele (d ¼ 1). We also considered an allele or haplotype frequency range of 0.1-0.5. On the basis of these assumptions, our analyses of NOS2A SNPs and haplotypes in 1648 trios had 495% power to detect very modest genotype relative risks (GRRs) of 1.3 and 1.5 for allele or haplotype frequencies as low as 0.3 and 0.1, respectively. Similar results for statistical power were observed for samples sizes of both 720 and 930 trios when considering a GRR as low as 1.5. Specifically, power ranged from 60-75% (allele or haplotype frequency ¼ 0.1) to 495% (allele or haplotype frequency ¼ 0.3). Power was more limited (for all sample sizes) to detect a GRR p1.3 when the allele or haplotype frequency was less common (0.1); however, power was much higher, even for sample sizes of 720 and 930 trios, to detect a GRR of 1.3 when the allele or haplotype frequency was 40.1 (50-80%). It is important to note that 48/50 or 96% of SNPs tested for association in this study had MAF 40.1; a total of 33/50 or 66% of SNPs had MAF X0.25. Power is expected to be much higher for the PDT analyses that utilized additional discordant sibpairs. Our power assessment suggests that the dataset was well powered to detect even the modest NOS2A effects. 57 
